StockReport.com is a 7:00 PM newsletter with a pertinent stock report every day, plus the lates market news.

Koninklijke Philips N.V. (NYSE: PHG), commonly known as Philips, is a Dutch multinational company focused on health technology. Founded in Eindhoven in 1891, the company evolved from a diversified electronics manufacturer into a specialist in healthcare products, systems and services. Philips is legally registered in the Netherlands and operates globally, supplying equipment and solutions to hospitals, clinics, healthcare providers and consumers across Europe, the Americas and Asia.
Philips’ principal activities center on medical technologies and personal health. Its medical portfolio includes diagnostic imaging systems (such as MRI, CT and ultrasound), image‑guided therapy solutions, patient monitoring and clinical informatics. The company also develops products and systems for respiratory care and sleep health, alongside a range of consumer‑oriented personal health products, including oral‑care and grooming devices. In addition to hardware, Philips offers software, data analytics and service agreements intended to integrate devices into clinical workflows and support care delivery.
Over recent decades Philips has pursued a strategic transformation to concentrate on HealthTech: divesting non‑core businesses (the lighting business was floated as Signify in 2016) and investing in digital health, clinical workflows and aftermarket services. Its go‑to‑market model combines direct sales to large healthcare organizations with channel partners and service networks, supported by global R&D and manufacturing sites aimed at serving regional and international customers.
Philips is led by an executive management team focused on innovation, operational improvement and expanding its health technology footprint. The company emphasizes partnerships with healthcare providers and technology firms to advance diagnostics, treatment and patient monitoring, with an ongoing focus on software, connectivity and outcomes‑oriented solutions in healthcare delivery.




Kraft Heinz said Wednesday it's pausing its plans to split into two companies.Steve Cahillane, a former Kellogg Co. chief who became CEO of Kraft Heinz on Jan. 1, said he wants to ensure that all of the company's resources are focused on profitable growth. “I have seen that the opportunity is larger...
The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the latest sign of the FDA’s heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr....